BerGenBio ASA (BGBIO.OL)
| Previous close | 0.1448 |
| Open | 0.1448 |
| Bid | 0.1416 x 0 |
| Ask | 0.1428 x 0 |
| Day's range | 0.1410 - 0.1500 |
| 52-week range | 0.0750 - 1.7440 |
| Volume | |
| Avg. volume | 43,546,021 |
| Market cap | 556.6M |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings date | 29 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.02 |
PR NewswireBerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m).
PR NewswireBerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented "Investigating the effects of AXL inhibition during respiratory viral infections" during the 6th Forum on Respiratory Infections in Glasgow, Scotland.
PR NewswireBerGenBio Reports Third Quarter 2023 Financial Results
BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended September 30, 2023, and provided a business update.
